BUZZ-Voyager Therapeutics rises after Wedbush starts with 'outperform'

Reuters2024-11-29

** Biotech company Voyager Therapeutics' shares rise 6.9% to $6.18 premarket

** Wedbush analyst Yun Zhong starts coverage on stock with "outperform" rating and PT at $11; previous Wedbush analyst covering stock had a "neutral" rating and PT of $7

** The new PT is a 90.3% upside to the stock's last close

** Brokerage says positive data from VYGR's programs targeting neurodegenerative disorders, including Alzheimer's and ALS, have boosted their confidence

** Wedbush says shares are trading low, creating an "attractive investment opportunity" despite the high risks of early-stage treatments

** All ten brokerages rate the stock "buy" or higher; their median PT is $18 - LSEG

** As of last close, stock has fallen 31.5% YTD

(Reporting by Kamal Choudhury)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment